Search

Start Over Subject protokoly antitumorózní kombinované chemoterapie Type model:article Date 2010

1. Evropská unie schválila lék Herceptin k léčbě HER2-pozitivního metastazujícího karcinomu žaludku

Creator:
Pešina, Jiří
Type:
model:article, article, Text, klinické zkoušky - fáze III, and TEXT
Subject:
lidé, nádory žaludku--farmakoterapie, monoklonální protilátky, receptor erbB-2--antagonisté a inhibitory, protokoly antitumorózní kombinované chemoterapie, deoxycytidin--antagonisté a inhibitory, fluorouracil--antagonisté a inhibitory, trastuzumab, and capecitabin
Language:
Czech
Description:
Jiří Pešina
Rights:
http://creativecommons.org/publicdomain/mark/1.0/ and policy:public

2. Preliminary study results of multiple drug resistance in patients with advanced types of colorectal cancer

Creator:
Navruzov, S. N., Abdujapparov, S. B., Pulatov, D. A., Islamov, H. D., Matniyazova, Sh. Ya, and Akbarov, E. T.
Format:
braille, electronic resource, remote, and elektronický zdroj
Type:
model:article, article, Text, statistics, and TEXT
Subject:
léková rezistence, nádory rekta--terapie, protokoly antitumorózní kombinované chemoterapie, staging nádorů, výsledek terapie, dospělí, staří, ženské pohlaví, lidé, mužské pohlaví, and lidé středního věku
Language:
English
Description:
In the department of coloproctology of NORC MH RUz 17 patients with disseminated forms of colorectal cancer was made the study of oncogenes and complex treatment by 2 protocols using FOLFOX4 regime and FOLFIRI regime. In second protocol there used 2 sessions of endolymphatical polychemotherapy FOLFOX4 regime against EHFhyperthermia. All patients were performed additional investigations directed to study the presence of multiple drug resistance in them where definition of р53, bcl2 oncogene expression. In our observations we followed resistance to FOLFOX4 scheme in 4 patients, and to FOLFIRI scheme in 2 cases. In our studies hyperexpression of oncoproteine р53 was correlated with the effect of conducted therapy whereas hyperexpr, Navruzov S. N., Abdujapparov S. B., Pulatov D. A., Islamov H. D., Matniyazova Sh. Ya., Akbarov E. T., and Literatura
Rights:
http://creativecommons.org/publicdomain/mark/1.0/ and policy:public

3. Role of lymphatic polychemotherapy and EHF therapy in treatment of colorectal cancer complicated by carcinomatosis of abdominal cavity

Creator:
Akbarov, E.T., Navruzov, S.N., Abdujapparov, S.B., and Islamov, H.D.
Format:
braille, electronic resource, remote, and elektronický zdroj
Type:
model:article, article, Text, statistics, and TEXT
Subject:
kolorektální nádory--komplikace--terapie, břišní dutina--patologie, chemoradioterapie adjuvantní--metody, peritoneum--patologie, organoplatinové sloučeniny--aplikace a dávkování--terapeutické užití, pooperační péče, protokoly antitumorózní kombinované chemoterapie, kolostomie, kombinovaná terapie, výsledek terapie, and lidé
Language:
English
Description:
Aim: to improve treatment results of colorectal cancer, complicated carcinomatosis of abdominal cavity, by associated using of endolymphatic chemotherapy (ELCT) and local extremely high frequency (EHF) therapy. Igroup – 21 people (33.3%) performed colostomy, then neoadjuvant systemic chemotherapy by the scheme FOLFOX4. It was held two cycles, after two cycles their were received cytoreductive surgery; II group – 26 people (41,3%) received cytoreductive operations with early postoperative intraabdominal chemotherapy by oxaliplatin (200 mg/m(2) at day 1 and 5FU 650 mg/m(2) from days 1 to 4. III group – 16 people (25,4%) also performed colostomy, then used 2 courses of ELCT with local EHF therapy and all patients were received cytoreductive operations. ELCT was carried out injecting oxaliplatin100 mg/m(2) a day during 12 hours and then 5 – FU in doze of 600 mg/m2 a day during 72 hours by the instrumentality of the dozer and LV200 mg/m(2) (2h intravenous infusion). During ELCT patients received local EHF therapy in abdominal cavity for an hour. After chemotherapy the partial regress of tumor observed in 1st group in 4,8 % and in 3rd –37,5 %, stabilization of process noted in 28,6 and 50% cases, progressing –66,7 and 12,5% cases correspondingly to groups. Histomorphologic study of malignant foci after ELCT+EHF therapy showed reduction of specific area of parenchyma cancer cell from 57 till 39% simultaneous growth of stroma from 40 till 58% and in necrosis area – from 1,8 till 2,5%. Mitotic activity of tumor cells in the 1st group decreased (average in 22 un.), but in 3rd group it decreased until 11 units. Analysis of life span showed that in 1st group of patients 2year survival rate was 66,7%. In 2nd group of patients 2year survival rate was 42,3%. ELCH+EHFtherapy has high clinic efficacy and promotes to decrease terms of progression of tumor process, increases life span from 0 till 24% and quality of life of the patients. ELCH+EHFtherapy brings to reduction of specific area of parenchyma in cancer cells from 57 till 39% with simultaneous growth of stroma area from 40 till 58% and necrosis area – from 1,8 till 2,5%. ELCT+EHFtherapy lowers mitotic activity of tumor cells, activates apoptosis, hemodynamic and metabolic rates., Akbarov E.T., Navruzov S.N., Abdujapparov S.B., Islamov H.D., and Literatura
Rights:
http://creativecommons.org/publicdomain/mark/1.0/ and policy:public